1800-272-662
Shopping Cart 0
countryflagAU
Login

CureVac NV

Healthcare US CVAC

NoneUSD
-(-%)

Last update at 2026-02-05T21:14:13.988151Z

Day Range

--
LowHigh

52 Week Range

2.2112.36
LowHigh

Fundamentals

  • Previous Close 4.66
  • Market Cap823.20M
  • VolumeNone
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-268.89798M
  • Revenue TTM59.00M
  • Revenue Per Share TTM0.26
  • Gross Profit TTM -91.54900M
  • Diluted EPS TTM-1.31

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -249.15500M -412.49800M -129.80000M -100.12500M -71.13100M
Minority interest - - - - -
Net income -249.02900M -411.71600M -129.07400M -99.87300M -71.24100M
Selling general administrative 88.99M 87.20M 45.03M 42.18M 20.41M
Selling and marketing expenses 0.42M 1.74M 0.73M 1.75M 1.08M
Gross profit -116.57300M -135.20500M 34.73M -10.56700M -4.87300M
Reconciled depreciation 23.74M 15.67M 10.67M 7.16M 3.78M
Ebit -249.45700M -412.26300M -124.00200M -99.49800M -70.85600M
Ebitda -223.10200M -386.48600M -109.80000M -91.50100M -67.07500M
Depreciation and amortization 26.36M 25.78M 14.20M 8.00M 3.78M
Non operating income net other - - - - -
Operating income -249.45700M -412.26300M -124.00200M -99.49800M -72.82400M
Other operating expenses 318.27M 515.25M 158.70M 116.91M 85.69M
Interest expense 3.71M 10.34M 22.10M 1.46M 0.28M
Tax provision -0.12600M -0.78200M -0.72600M -0.25200M 0.11M
Interest income 4.01M 10.10M 2.07M 0.83M 1.97M
Net interest income 0.30M -0.23500M -20.00000M -0.62700M 1.69M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.12600M -0.78200M -0.72600M -0.25200M 0.11M
Total revenue 67.42M 102.99M 48.90M 17.42M 12.87M
Total operating expenses 134.28M 277.06M 158.70M 88.93M 67.95M
Cost of revenue 183.99M 238.19M 14.17M 27.98M 17.74M
Total other income expense net 0.30M -0.23500M -5.79800M -0.62700M 1.69M
Discontinued operations - - - - -
Net income from continuing ops -249.02900M -411.71600M -129.80000M -99.87300M -71.24100M
Net income applicable to common shares - -411.71600M -129.12200M -99.87300M -71.24100M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 788.90M 860.47M 1158.24M 1511.36M 130.62M
Intangible assets 15.88M 19.32M 13.24M 14.15M 5.70M
Earning assets - - - - -
Other current assets 15.25M 5.34M 49.24M 48.29M 1.15M
Total liab 271.53M 327.22M 469.77M 800.01M 173.42M
Total stockholder equity 517.37M 533.25M 688.48M 711.35M -42.80200M
Deferred long term liab - 0.30M 0.52M 1.03M 0.97M
Other current liab 90.51M 46.22M 176.25M 68.78M 13.27M
Common stock 26.90M 23.40M 22.45M 21.66M 0.73M
Capital stock 26.88M 23.40M 22.45M 21.66M 0.73M
Retained earnings -1567.27210M -1305.81400M -1056.78500M -645.06900M -515.94700M
Other liab - - 86.61M 500.35M 68.19M
Good will 12.47M 12.46M - - -
Other assets 0.00000M 2.97M 5.56M 7.46M 6.34M
Cash 402.78M 495.80M 811.46M 1322.59M 30.68M
Cash and equivalents - - - - -
Total current liabilities 186.54M 156.22M 357.73M 247.62M 28.09M
Current deferred revenue 44.62M 36.78M 55.75M 157.99M 7.48M
Net debt -360.92533M -453.71100M -782.57200M -1292.50600M 48.46M
Short term debt 5.01M 4.98M 3.47M 3.23M 2.00M
Short long term debt - - - - -
Short long term debt total 41.86M 42.09M 28.89M 30.09M 79.15M
Other stockholder equity 2057.81M -1.48100M -5.81700M 1358.85M 493.37M
Property plant equipment - - 200.39M 100.59M 61.69M
Total current assets 478.78M 584.03M 940.02M 1389.85M 57.17M
Long term investments - - - - -
Net tangible assets - 501.49M 676.20M 697.89M -48.21800M
Short term investments 2.66M 4.49M 4.65M 2.62M 1.46M
Net receivables 35.92M 39.44M 18.50M 1.82M 17.69M
Long term debt - - - - 65.02M
Inventory 24.82M 23.99M 56.16M 14.53M 6.20M
Accounts payable 46.40M 68.25M 122.26M 17.62M 5.33M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.06706M 1817.15M 1728.62M 1334.76M 472.42M
Additional paid in capital - - - - -
Common stock total equity - - - 21.66M 0.73M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other -14.16832M 1.67M 1.22M 1.09M 0.97M
Deferred long term asset charges - - - - -
Non current assets total 310.12M 276.44M 218.22M 121.50M 73.44M
Capital lease obligations 41.82M 42.09M 28.89M 55.28M 14.13M
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -93.49900M -127.90100M -1.16100M 28.18M -4.26400M
Change to liabilities 0.00000M 271.26M 650.81M -0.28000M 9.62M
Total cashflows from investing activities - -127.90100M -45.27400M 28.18M -4.26400M
Net borrowings - -28.18300M -47.88400M 67.98M -0.11200M
Total cash from financing activities 63.17M 344.96M 819.83M 67.98M -0.11200M
Change to operating activities - -3.13800M -47.63300M 0.30M -5.77000M
Net income -249.15500M -412.49800M -129.84800M -100.12500M -71.13100M
Change in cash -315.66700M -511.12900M 1291.91M 9.30M -78.27300M
Begin period cash flow 811.46M 1322.59M 30.68M 21.38M 99.65M
End period cash flow 495.80M 811.46M 1322.59M 30.68M 21.38M
Total cash from operating activities -286.17700M -733.12800M 522.40M -86.96300M -74.11000M
Issuance of capital stock 66.48M 404.06M 867.72M - 0.00000M
Depreciation 23.74M 15.67M 10.67M 7.16M 3.78M
Other cashflows from investing activities - - 3.24M 2.33M 2.33M
Dividends paid - - - - -
Change to inventory -47.85100M -227.46000M -8.33400M -3.24600M 0.88M
Change to account receivables -16.68200M -19.82000M -32.30100M -10.11700M -5.59500M
Sale purchase of stock - -34.10100M - - -
Other cashflows from financing activities 0.91M 3.19M 49.86M 69.89M -4.26400M
Change to netincome - -361.07000M 30.68M 19.09M -5.77900M
Capital expenditures 93.22M 127.90M 47.35M 12.22M 14.72M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -125.56300M -69.54700M 578.57M -22.65100M -1.08500M
Stock based compensation 9.19M 14.96M 14.24M 19.56M -4.24800M
Other non cash items 57.20M -480.73600M 51.63M 9.93M -1.47900M
Free cash flow -379.39900M -861.02900M 475.05M -99.18700M -88.83300M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CVAC
CureVac NV		 - -% - - 9.17 15.20 1.01 4.66 -0.721
NVO
Novo Nordisk A/S		 0.11 0.28% 38.83 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 0.005 0.01% 38.74 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -6.79 1.36% 492.38 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 2.63 0.34% 774.66 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.

CureVac NV

Friedrich-Miescher-Strasse 15, Tübingen, Germany, 72076

Key Executives

Name Title Year Born
Dr. Franz-Werner Haas L.L.M., LL.M., LLD, Ph.D. CEO, Member of Management Board & MD 1970
Mr. Pierre Kemula B.Sc. MD, CFO & Member of Management Board 1975
Dr. Ulrike Gnad-Vogt M.D., Ph.D. Interim Chief Devel. Officer, Sr. VP & Area Head of Oncology and Member of Exec. Board 1972
Dr. Igor Splawski M.Sc., Ph.D. Chief Scientific Officer & Member of Management Board 1969
Dr. Antony Blanc Ph.D. MD, Chief Bus. Officer, Chief Commercial Officer & Member of Management Board 1970
Mr. Malte Greune Ph.D. COO, Member of Management Board & MD 1965
Dr. Sarah Fakih VP Corp. Communications & Investor Relations NA
Mr. Marco Rau L.L.M., Ph.D. Gen. Counsel NA
Mr. Thorsten Schuller Head of Corp. Communications NA
Slavica Stevanovic-Heck Head of HR NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.